Parameter
| Biomarker | PIK3CA | Full name | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Molecular Type | Nucleic acid（DNA） |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis |
| Disease | Endometrial Cancer | Disease Subtypes | / | ||
| Organ | Endometrium | Test Sample / Technology Platform | Whole blood / Tumor tissue (NGS, ARMS-PCR) | ||
| Pathobiological Mechanisms | The oncogene is mutated to activate the PI3K/AKT signaling pathway, thereby promoting the survival, proliferation and drug resistance of tumor cells. | ||||
| Clinical Availability Status | Clinically applicable (target-guided): The mutation rate is approximately 20%-30%. Mutant patients are sensitive to PI3K inhibitors. | ||||
| Notes and Dynamics | MTOR inhibitors (such as everolimus) have shown therapeutic potential in patients with PIK3CA mutations. | ||||